Asset Details
Do you wish to reserve the book?
Local Delivery of Neurotrophin-3 and Anti-NogoA Promotes Repair After Spinal Cord Injury
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Local Delivery of Neurotrophin-3 and Anti-NogoA Promotes Repair After Spinal Cord Injury
Do you wish to request the book?
Local Delivery of Neurotrophin-3 and Anti-NogoA Promotes Repair After Spinal Cord Injury
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Local Delivery of Neurotrophin-3 and Anti-NogoA Promotes Repair After Spinal Cord Injury
2016
Overview
Tissue and functional repair after spinal cord injury (SCI) continue to elude researchers. Neurotrophin-3 (NT-3) and anti-NogoA have been shown to promote axonal regeneration in animal models of SCI; however, localized and sustained delivery to the central nervous system (CNS) remains a critical challenge for these and other macromolecular therapeutics. An injectable drug delivery system (DDS) has previously been developed, which can provide safe local delivery to the spinal cord. This DDS, composed of poly(lactic-co-glycolic acid) (PLGA) nanoparticles (nps) dispersed in a hyaluronan methylcellulose hydrogel, was adapted for the tunable bioactive delivery of NT-3 and anti-NogoA. Furthermore, the combined delivery of NT-3 and anti-NogoA from the DDS in an impact/compression model of SCI increases axon density and improves locomotor function. The benefits of this np/hydrogel DDS observed for NT-3 and anti-NogoA demonstrate the utility of the DDS as a local delivery strategy for protein therapeutics to the CNS.
Publisher
Mary Ann Liebert, Inc,SAGE Publications
Subject
/ Drug Carriers - pharmacology
/ Female
/ Neurotrophin 3 - pharmacology
/ Nogo Proteins - antagonists & inhibitors
/ Rats
/ Spinal Cord Compression - drug therapy
/ Spinal Cord Compression - metabolism
/ Spinal Cord Compression - pathology
/ Spinal Cord Compression - physiopathology
/ Spinal Cord Injuries - drug therapy
/ Spinal Cord Injuries - metabolism
/ Spinal Cord Injuries - pathology
/ Spinal Cord Injuries - physiopathology
We currently cannot retrieve any items related to this title. Kindly check back at a later time.